Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

<p>The first remdesivir double-blind, placebo-controlled clinical trial for treating COVID-19 was published recently in&nbsp;<em>Lancet</em>.&nbsp;A member of the trial&rsquo;s data safety monitoring board&nbsp;is&nbsp;Weichung Shih, PhD. Shih discussed the role of biostatisticians in protecting data integrity for clinical trials and the challenges during the COVID-19 pandemic.</p>

Biometrics Expert Discusses Data Integrity for COVID-19 Clinical Trials

Issues can include bias, result repeatability